The Insulin-like growth factor (IGF)/IGF-receptor pathway with its scaffolding proteins Insulin Receptor Substrate (IRS)1 and IRS2 are crucial regulators of metabolism and progression in metastatic colorectal cancer (mCRC). The goal of the study was the identification of predictive and prognostic markers among IRS1, IRS2, IGF1 and IGF-1R SNPs in mCRC patients enrolled in the FIRE-3 trial. Four SNPs of IRS (IRS1 rs1801278, rs1801123; IRS2 rs1805097, rs2289046) and four SNPs of IGF1-IGFR1 (rs6214, rs6220, rs2946834, rs2016347) were analyzed by PCR/direct-sequencing in the FIRE-3 trial. The relation of SNPs with PFS and OS was evaluated through Kaplan-Meier method and log-rank test in the overall population and in subgroup according to RAS status and treatment arm. In the overall population IRS1 rs1801123 C/-carriers ( N5 105 The Insulin Growth Factor-1 (IGF)-/Insulin-like Growth Factor-Receptor1 (IGF-1R) pathway is a key mediator of the response of tumor cells to the metabolic microenvironment and the regulation of tumor cell metabolism, proliferation, survival and angiogenesis. [1] [2] [3] This signaling pathway has been identified as a critical determinant of colorectal cancer (CRC) development, 2,3 and many evidences showed hyperinsulinemia as determinant of CRC risk as well as possible prognostic factor. [4] [5] [6] [7] Insulin receptor substrate (IRS) 1 and IRS2 are scaffolding proteins regulating downstream signaling of IGF/IGF-1R. They activate and regulate phosphoinositide 3-kinase (PI3K) and extracellular signal regulated kinase (ERK) pathways that are implicated in metabolism and protein synthesis, cell growth as well as key regulators of colorectal cancer development and progression and tightly connected to the EGFR signaling pathway.
The Insulin-like growth factor (IGF)/IGF-receptor pathway with its scaffolding proteins Insulin Receptor Substrate (IRS)1 and IRS2 are crucial regulators of metabolism and progression in metastatic colorectal cancer (mCRC). The goal of the study was the identification of predictive and prognostic markers among IRS1, IRS2, IGF1 and IGF-1R SNPs in mCRC patients enrolled in the FIRE-3 trial. Four SNPs of IRS (IRS1 rs1801278, rs1801123; IRS2 rs1805097, rs2289046) and four SNPs of IGF1-IGFR1 (rs6214, rs6220, rs2946834, rs2016347) were analyzed by PCR/direct-sequencing in the FIRE-3 trial. The relation of SNPs with PFS and OS was evaluated through Kaplan-Meier method and log-rank test in the overall population and in subgroup according to RAS status and treatment arm. In the overall population IRS1 rs1801123 C/-carriers (N5 105) achieved significantly worse OS compared to T/T (N 5 464) in univariate (HR 5 The Insulin Growth Factor-1 (IGF)-/Insulin-like Growth Factor-Receptor1 (IGF-1R) pathway is a key mediator of the response of tumor cells to the metabolic microenvironment and the regulation of tumor cell metabolism, proliferation, survival and angiogenesis. [1] [2] [3] This signaling pathway has been identified as a critical determinant of colorectal cancer (CRC) development, 2, 3 and many evidences showed hyperinsulinemia as determinant of CRC risk as well as possible prognostic factor. [4] [5] [6] [7] Insulin receptor substrate (IRS) 1 and IRS2 are scaffolding proteins regulating downstream signaling of IGF/IGF-1R. They activate and regulate phosphoinositide 3-kinase (PI3K) and extracellular signal regulated kinase (ERK) pathways that are implicated in metabolism and protein synthesis, cell growth as well as key regulators of colorectal cancer development and progression and tightly connected to the EGFR signaling pathway. 8, 9 IRS1 is overexpressed in CRC patients and has been associated with cancer progression and development of metastases. IRS2 mRNA and protein expression positively correlate with normal colorectal epithelium transitioning to adenoma, and subsequently, to adenocarcinoma. 10, 11 Amplification and mutations of IRS2 were recently identified in tumors with increased sensitivity to anti-EGFR therapy.
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IRS1 and IRS2 polymorphisms have also been independently associated with increased CRC risk. In particular carriers of IRS1 rs1801278 T/-genotype showed higher incidence of CRC, while patients with IRS2 rs1805097 C/T genotype had significantly reduced the risk of developing CRC. 13, 14 IGF-1R is frequently overexpressed in human colon cancer cells 15 and has been related to the promotion of growth and malignant transformation of adenomatous polyps 16 and to the development of distant metastases in murine models. The activation of insulin/IGF-dependent pathways has been identified as a possible mechanism of CRC resistance to conventional and targeted therapeutic agents and in particular to antiEGFRs. 17, 18 This observation is supported by the identification of a strong cross talk activity between IGF-1R and EGFR blockade and their downstream signaling pathways. When IGF-1R signaling is up regulated it might be able to overcome the inhibitory activity of anti-EGFRs leading to the activation of RAS and PI3K/Akt pathways and stimulating proliferation, cell growth and apoptosis inhibition. 9 Our group retrospectively investigated the association of six potentially functional IGF1 and IGF1R polymorphisms with survival parameters in a cohort of 130 chemotherapy refractory mCRC patients enrolled in the IMC-0144, a phase II clinical trial of cetuximab monotherapy. In univariate and multivariable analyses five IGFpathway SNPs were significantly associated with progressionfree-survival (PFS) and/or overall survival (OS). The effect of the SNP in terms of outcome prediction was even more significant in the subgroup of patients with KRAS wild type tumor 19 (Supporting Information Fig. 1 shows the IGF-IGFR-IRS pathway).
The present study aimed at (i) the identification of a prognostic/predictive role for selected IRS1 and IRS2 SNPs and (ii) the prospective validation of previous findings on IGF-IGF-1R SNPs in the randomized phase III FIRE-3 trial. 20 
Material and Methods

Patient population
A total of 614 tissue samples deriving from primary of patients treated with first-line FOLFIRI plus bevacizumab and FOLFIRI plus cetuximab in the randomized, open-label, phase III FIRE-3 trial 20 were available for the present analysis. Patients had histologically confirmed stage IV colorectal adenocarcinoma, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and did not receive prior treatment for metastatic disease, nor exposure to irinotecan, cetuximab (Arm A), or bevacizumab (Arm B). Standard inclusion and exclusion criteria were applied. Patients received bevacizumab 5 mg/kg or cetuximab 400 mg/kg, followed by irinotecan 180 mg/m2, leucovorin 200 mg/m2, 5-fluorouracil 400 mg/m2 bolus infusion and 5-fluorouracil 2,400 mg/m2 as a 48-hr continuous infusion. Treatment was administered every 2 weeks until disease progression, intolerable toxicities, or patient withdrawal. Responses were measured by contrast-enhanced computed tomography (CT) scans after 6 and 12 weeks of treatment, and every 10 weeks thereafter according to RECIST v1.0.
SNP selection
IRS1 and IRS2 polymorphisms were chosen for investigation according to the following criteria: minor allele frequency>5% in Caucasians according to the ENSEMBL database (http://www.ensembl.org/index.html) citation on Pubmed and possible relation with cancer functional or predicted functional relevance of gene transcription or protein expression. Functional significance was predicted based on information provided by the National Institute of Environmental Health Science SNP Function Prediction, Queen's University F-SNP, and the location of the SNP in the protein-coding region of the gene (http:// snpinfo.niehs.nih.gov/snpinfo/snptag.htm).
IGF1 and IGFR1 polymorphisms, following the above specified inclusion criteria, were further selected based on the results of our previous study if an association with either PFS or OS was maintained in the multivariable model. 19 Supporting Information Table 1 shows genes, SNP identification numbers, location and adopted forward and reverse primers. Genotyping procedures are described in the supplementary informations.
Genotyping
Genomic DNA was extracted from formalin-fixed paraffinembedded (FFPE) tissues of patients using the QIAmp Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol (www.qiagen.com). PCR-based direct DNA sequence analysis using ABI 3100 A Capillary Genetic Analyzer and Sequencing Scanner v1.0 (Applied Biosystems, Waltham, MA) was performed for genotyping the SNPs. The extracted DNA was amplified using the primer sets shown in Supporting Information Table 1 , and analyzed by PCR-based direct DNA sequencing. The investigator analyzed sequencing data using the ABI Sequencing Scanner v1.0 (Applied Biosystems, Life Technologies, Grand Island, NY) and was blinded to the clinical data set.
What's new?
Newly identified genetic variants could predict survival in colorectal cancer. The insulin growth factor (IGF) and IGF-1R pathway mediate the growth and spread of tumor cells. These authors studied polymorphisms in IGF, IGF-1R, and two downstream scaffolding proteins, IRS1 and IRS2 to determine whether they could help predict outcomes. They confirmed previous findings that people carrying a particular SNP in IGF1 have better survival; they also picked out a SNP in IRS1 that predicts outcome in patients with wild-type RAS. These markers could help identify patients who are more likely to benefit from drugs that target the IGF-1R pathway.
Statistical methods
The primary objective of the study was the exploratory analyses on the prognostic/predictive role of IRS1 and IRS2 SNPs in mCRC patients enrolled in the randomized phase III FIRE-3 trial. Subgroup analyses according to treatment arm, KRAS and extended RAS status were preplanned.
Secondary objective was the validation of previous findings on IGF1 and IGFR1 SNP as potential predictive/prognostic molecular markers for cetuximab efficacy in mCRC patients. The above specified subgroup analyses were performed.
Primary and secondary clinical endpoints were OS and PFS, respectively. OS was defined as the time from treatment start to death due to any cause. PFS was defined as the time from treatment start to first documented disease progression or death due to any cause. Patients were censored at the time of last follow-up if no events occurred. Patients were defined as responders when achieving complete or partial response and non-responders when stable or progressive disease occurred as defined by RECIST 1.0 criteria. Differences between baseline characteristics of Arm A and Arm B patients were analyzed by means of v 2 test for categorical factors and the Wilcoxon rank sums test for continuous variable.
Allelic distribution of polymorphisms was tested for deviation from Hardy-Weinberg equilibrium (HWE) using v 2 test.
Linkage disequilibrium among SNPs was assessed using D' and r 2 values, and the haplotype frequencies of the two genes were inferred using HaploView version 4.2 (http://www. broad.mit.edu/mpg/haploview). Kaplan-Meier curves, logrank test and Cox proportional hazard models were applied to evaluate the association between SNPs with PFS and OS in univariate and multivariable model. The association between SNPs and the baseline characteristics was examined using v 2 test. Baseline characteristics that remained significantly associated with PFS and OS in multivariable model after backward elimination procedure with p < 0.1 criteria were included in the final model. p values for all SNPs were adjusted for multiple testing using p act method, a modified test introduced by Conneely and Boehnke that was applied for the correlated tests due to linkage disequilibrium and different modes of inheritance considered. 21 Fisher's exact test was used to evaluate the association between SNPs and tumor response. The true mode of inheritance of SNPs was not a priori established, and we assumed a codominant, dominant or recessive model whenever appropriate. At the time of the current data analyses, we observed 391 deaths out of 600 evaluable patients. We would have 80% power to detect the effect of a SNP on OS with HRs ranged from 1.33 to 1.59 using two-sided 0.05-level log-rank test when the dominant model with the minor allele frequencies of 0.05 to 0.40 is considered. SAS 9.4 (SAS Institute, Cary, NC) was used to perform all analyses. All tests were two-sided at a significance level of 0.05.
Results
600 out of 614 patients were evaluable for the present study: 305 patients were enrolled in arm A and 295 enrolled in arm B. Main patient's characteristics are described in Supporting Information Table 2 : 93% of patients in arm B presented T stage >2 compared to those in arm A (89%; p 5 0.006). No other relevant differences were observed according to treatment arm. Details regarding the number of successfully genotyped samples in evaluable patients for each SNP are described in Supporting Information Table 1 .
Median follow-up, median PFS and median OS were 40.9, 9.9 and 24.8 months in the overall population; 41.8, 9.6 and 26.5 months in arm A; and 40.8, 10.1 and 24.2 months in arm B.
Association of patient baseline characteristics with PFS and OS in the overall population and the two arms were summarized in Supporting Information Tables 3-5. In the overall population, ECOG PS 1, right-sided primary tumor, RAS and BRAF mutations T stage> 2 were statistically associated with worse PFS and OS in the univariate model. An association with worse PFS was observed in females while an association with worse OS was identified in patients with liver metastases, number of metastatic sites >2, synchronous metastatic disease, and KRAS mutations. In respect to different treatment arms, the same factors were associated with PFS or OS. However, the effect of RAS mutations, RAS mutations and T stage was not significant in patients treated with FOLFIRI plus bevacizumab. All the genotyped SNPs were on HWE (p > 0.05) and the frequencies of the selected SNPs were in line with literature data. IRS2 rs2289046 and IRS2 rs1805097 were in linkage disequilibrium with D' of 0.72 and r 2 of 0.41. Other disequilibrium was not observed.
Primary objective results
In the overall population patients with IRS1 rs1801123 C/-(N Tables 6 and 7) .
Secondary objective results
In the overall population patients with IGF1 rs2946834 T/-(N 5 280) achieved an improved PFS compared to C/C variant carriers (N 5 257) in the univariate analyses (median PFS T/-10.5 vs. C/C 9. (Table 1) . Similar results were observed among KRAS wild type patients (Table  2) . It remained significantly associated with PFS after multiple testing in both overall patients and KRAS wild type patients (adjusted p 5 0.074 and 0.007, respectively).
In the RAS wild type subgroup patients with IGF1 rs2946834 T/-retained their significantly improved PFS compared to C/C variant carriers at both univariate (HR 5 0. Table 7 ).
Discussion
The present study identified IRS1 rs1801123 C/T SNP as prognostic factor for metastatic CRC patients enrolled in the FIRE-3 trial irrespectively from treatment with bevacizumab or cetuximab. Interestingly, in subgroup analyses of RAS wild type patients the prognostic effect of IRS1 rs1801123 C/T was confirmed and no effect was observed among patients carrying RAS mutations. Although an association of IRS SNP and CRC risk was already demonstrated, to the best of our knowledge this is the first report showing a prognostic role for IRS1 SNP with particular regard to RAS wild type mCRC patients.
IRS1 rs1801123 C/T SNP has been associated with splicing and post-transcriptional regulation of IRS1 protein; IRS-1 2), and stratified by treatment arm (arm A vs. arm B) ( ‡); p values adjusted for multiple testing were shown in parentheses.). 2), and stratified by arm ( ‡); p values adjusted for multiple testing were shown in parentheses.). 2),
and stratified by arm ( ‡); p values adjusted for multiple testing were shown in parentheses.) .
expression appears inversely correlated to CRC differentiation and it shows higher immunostaining levels in hepatic metastases compared to both primary CRC and paired colonic epithelium. All the above-mentioned studies lead to hypothesize a role for IRS-1 in CRC progression and development of liver metastasis. 10 IRS1 rs1801123 was also significantly associated with lymph node involvement in a cohort of breast cancer patients with locally invasive tumor and estrogen receptor sensitivity.
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IRS1 is considered a marker of active IGF-1 signaling pathways in tumors and its phosphorylation mediated by IGF-1R, transmit mitogenic, anti-apoptotic, and antidifferentiation signals to the cell through the PI3K and the ERK pathways. 23 IRS1 is constitutively activated in many human tumors 24 and it's critical for tumor growth, it has been demonstrated that down regulation of IRS1 (by antisense or siRNA procedures) reverses the transformed cancer phenotype. 25 Moreover it has been implicated in resistance to EGFR and mTOR inhibitors. 26 Recently a new family of IGF-IR/IRS-targeted agents named the NT compounds has been developed and showed promising preclinical activity in the inhibition of IRS proteins. In particular they act as competitive inhibitors of IGF-IR, promote inhibitory phosphorylation and degradation of IRS1 and IRS2 leading to the elimination of IRS1/2 and finally to cell death. 27 Among NT compounds, NT157 showed to prevent colorectal tumor development and caused durable regression of established tumors and attenuated metastatic growth in murine models and in human CRC cells. 28 Explorative subgroup analyses were performed in order to identify a possible predictive role for the selected SNPs and a prognostic role in a molecularly selected population of RAS wild type patients. No specific associations were identified according to treatment arm, suggesting no predictive effect for IRS1 and IRS2 SNPs to anti-EGFRs. However the interesting observation of a prognostic role for IRS1 SNPs in RAS wild type patients strengthens the biological rationale of our findings confirms the relation between the IGF-IGF-1R-IRS with the EGFR signaling pathway and underlines the importance of IRS1 as a new possible target in RAS wild type mCRC patients. Although we have to admit that the statistical significance was lost when applying correction for multiple testing, our results are still relevant as hypothesis generating findings and might be validated in future trials.
As limitation of our results, due to the exploratory nature of those findings and to the unavailability of adequate tissue samples, we did not perform additional expression analyses aiming at the identification of possible correlations between IRS1 rs1801123 C/T SNP and IRS1 expression. IRS1 rs1801123 C/T SNP has been associated with splicing and post-transcriptional regulation of IRS1 protein, we can hypothesize that IRS1 rs1801123 C allele might be associated with higher IRS1 expression and worse prognosis in CRC patients.
On the other hand, we prospectively confirmed a prognostic role for IGF1 rs2946834 in the overall population of FIRE-3 trial as well in the subgroup of molecularly selected RAS wild type patients. In our previous work multivariable models identified a significant association with PFS for IGF rs6214, IGF1 rs6220 and IGF1 rs2946834 and a significant association with OS for IGFR1 rs2016347 in the overall population of chemo-refractory mCRC patients treated with cetuximab monotherapy in the IMC-0144 trial. 29 An association with the subgroup of KRAS wildtype patients and PFS was observed for IGF1 rs6214 and IGF1 rs2946834. The lack of a control group and the tight connection of the IGF-IGFR1 with the EGFR downstream signaling pathway allowed us to hypothesize a possible predictive role of cetuximab efficacy for those SNPs. 22 In the present study, the predictive effect was denied and the prognostic role was confirmed since IGF1 rs2946834 predicted PFS in patients treated with FOLFIRI plus cetuximab and in those treated with FOLFIRI plus bevacizumab. The connection of IGF1 rs2946834 and rs6220 with RAS status in the prediction of mCRC prognosis was also confirmed. Such findings are supported by a strong biological rationale: IGF1 rs2946834 SNP is located in the 3 0 UTR of the IGF1 gene and affect mRNA stability and translational expression. This SNP has been related with circulating levels of IGF1 in breast cancer patients and high levels of IGF1 correlated with poor outcome in CRC and response to IGF-1R inhibition. [30] [31] [32] From a methodological point of view, the prospective verification of our previous findings further enforces the reliability of our results and underline the need of prospective validation of results obtained from genotyping studies. 33 From a more general perspective, the identification of specific prognostic factors in RAS wild type patients is crucial. Nowadays it is well known that it is not possible to refer to CRC patients as a homogeneous population since cases carrying RAS wild type have specific clinical characteristics, outcome and derive different benefit from treatment compared to RAS mutant. [34] [35] [36] [37] Our results confirm that IGF-IGFR1 pathway affects specifically RAS wild type tumors. Among RAS wild type patients IGF1 and IRS1 SNPs might allow to identify specific subgroup of patients.
IGF signaling has been proposed as an attractive target in the last few years for the development of novel anticancer therapeutics. 38 However, despite promising biological rationale and preclinical data, studies failed to provide definitive evidence that IGF-1R may represent a valid therapeutic target in solid tumors. 30, 31, [39] [40] [41] [42] As an example, in chemorefractory KRAS wild type mCRC patients, the phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, in combination with cetuximab and irinotecan failed to demonstrate an improvement of OS. 31, 32 Possibly, patients selection was not adequate and that might have influenced results of clinical trials. 43 Moreover it has been hypothesized that only in a minority of cases IGF-1R is activated and plays a crucial role. 44 Our results, if validated in clinical trials might allow identifying IRS1 and IGF1 SNPs as useful tool in order to select patients who benefit from anti-IGF-1R drugs.
